Introduction
Bicarbonate is a membrane-impermeable molecule central to cellular, blood and whole-body pH homeostasis. Transmembrane movement of bicarbonate is facilitated by integral membrane transport proteins (Sterling and Casey, 2002) . Many factors influence the rate of HCO 3 À transport.
However, interactions between bicarbonate transporters (BTs) and carbonic anhydrase (CA) enzymes have emerged as critical to bicarbonate flux (Vince and Reithmeier, 1998; Sterling et al, 2001 Sterling et al, , 2002a Gross et al, 2002; Loiselle et al, 2004) . CAs catalyze the reversible conversion between CO 2 and HCO 3 À , and thus both produce and consume the transport substrate of BT. Localization of CA to the surface of a BT maximizes the rate of bicarbonate transport by maximizing the transmembrane bicarbonate gradient local to the BT. The complex of a BT with a CA has been called a bicarbonate transport metabolon and is central to the physiology of these transporters. Other transport metabolons, consisting of a transporter and the enzyme that metabolizes the transport substrate, have yet to be identified, but there are many examples where the cellular physiology suggests they occur.
Three separate groups of proteins facilitate bicarbonate transport: SLC4a Cl À /HCO 3 À exchangers, SLC4a sodiumcoupled transporters and certain members of the SLC26a family (McMurtrie et al, 2004) . Within each of these groups there are now examples of CA/BT interactions, representing bicarbonate transport metabolons (Vince and Reithmeier, 1998; Sterling et al, 2001 Sterling et al, , 2002b Gross et al, 2002; McMurtrie et al, 2004) . SLC4a Cl À /HCO 3 À exchangers bind both cytosolic CAII and extracellular CAIV to maximize bicarbonate transport activity (Vince and Reithmeier, 1998; Sterling et al, 2001 Sterling et al, , 2002a . Functional and physical interactions between the human sodium-coupled NBC1 (SLC4a4) Na þ /HCO 3 À cotransporter and CAII have also been found (Gross et al, 2002) . A member of the SLC26A family, DRA (SLC26A3), also requires cytosolic CAII to manifest full HCO 3 À transport, but no evidence was found for CAII binding by DRA (Sterling et al, 2002b) . The present report is the first identification of an SLC26a BT that interacts physically with CA. In all, 14 mammalian CA isoforms, CAI-XIV (Schwartz, 2002) , catalyze the reversible hydration/dehydration of CO 2 and HCO 3 À , respectively. Ubiquitous cytoplasmic CAII is a 29 kDa polypeptide characterized by high enzymatic activity and great susceptibility to inhibition by sulfonamides such as acetazolamide (ACTZ) (Spicer et al, 1990) . CAII is strongly associated with the inner leaflet of the apical plasma membrane in human pancreatic duct cells, where it may couple to some HCO 3 À transport proteins (Mahieu et al, 1994; Alvarez et al, 2001b) . Members of the SLC4A anion exchanger (AE) family (Sterling and Casey, 2002) and the SLC26A anion transport gene family (Everett and Green, 1999) , mediate anion exchange at the plasma membrane of mammalian cells. The SLC26A family (SLC26A1-A11) transports a range of anionic substrates (Mount and Romero, 2004) . SLC26A6 has been cloned from both humans (SLC26A6) (Lohi et al, 2000; Waldegger et al, 2001 ) and mice (Slc26a6, also known as CFEX) (Knauf et al, 2001) .
Substrate anion specificity and transport stoichiometry of anion exchange by SLC26A6 have been studied. Using an anion exchange mechanism, SLC26A6 transports a variety of anions, including sulfate, formate, oxalate, nitrate, and iodide (Mount and Romero, 2004 (Ko et al, 2002; Alvarez et al, 2004; Chernova et al, 2005) , the anion transport stoichiometry of SLC26A6 is controversial. Mouse Slc26a6 has been reported to facilitate Cl À /HCO 3 À exchange by an electrogenic mechanism (Ko et al, 2002; Xie et al, 2002) . In contrast, a recent report found that Cl À /HCO 3 À exchange by both mouse Slc26a6 and the human ortholog, SLC26A6, was electroneutral (Chernova et al, 2005) . Slc26a6, identified in the brush border membrane of renal proximal tubule cells, has been reported as the candidate protein mediating Cl À /formate exchange, contributing to renal NaCl reabsorption (Knauf et al, 2001) . SLC26A6 is also abundant in small intestine, where it performs apical Cl À /HCO 3 À exchange . The phenotype of an Slc26a6 knockout mouse supports a role of the transporter in renal formate and oxalate transport and significant contribution to duodenal bicarbonate secretion (Wang et al, 2005) . SLC26A6 is also present in the heart and stomach Alvarez et al, 2004) . In pancreatic duct, which secretes a fluid containing up to 140 mM HCO 3 À , SLC26A6 has a major role in apical HCO 3 À secretion, stimulated by the cystic fibrosis gene product, CFTR (Ko et al, 2002; Simpson et al, 2005) . Failure of bicarbonate secretion leads to the pancreatic insufficiency prevalent in cystic fibrosis (CF) (Steward et al, 2005) . Protein kinase C (PKC) inhibits pancreatic bicarbonate secretion. The pancreas has a local renin-angiotensin system and, in exocrine pancreas, angiotensin II (AngII) receptor subtypes AT1 and AT2 are found in pancreatic ducts (Tsang et al, 2004) . AngII inhibits anion secretion in pancreatic cells, which is blocked upon PKC inhibition, suggesting that AngII acts through PKC (Cheng et al, 1999) . In addition, substance P inhibits an AE on the luminal membrane of pancreatic ducts, in a PKC-dependent manner. This PKC-inhibited AE is blocked by stilbene disulfonates (Hegyi et al, 2005) , in a mode consistent with SLC26A6. The effects of PKC on SLC26A6 have not, however, been studied previously.
Little is known about mechanisms that regulate SLC26A6 transport activity. A recent report showed reciprocal regulatory interaction between CFTR and the SLC26A transporters SLC26A3 and SLC26A6 when expressed in HEK293 cells (Ko et al, 2004) . SLC26A3 markedly activated CFTR, facilitated by PDZ ligands and binding of the SLC26A STAS domain to the CFTR R domain (Ko et al, 2004) . SLC26A family members share a conserved C-terminal cytosolic domain, which, interestingly, is also found in bacterial anti-sigma factor antagonists (Aravind and Koonin, 2000) . The STAS domain is named for sulfate transporters and bacterial anti-sigma factor antagonists. Expression of recombinant STAS domain activates CFTR (Ko et al, 2004) . In addition, CFTR and SLC26A transporters colocalize to the luminal membrane of native pancreatic duct cells.
This manuscript provides a possible molecular mechanism for the observation that PKC inhibits pancreatic bicarbonate secretion. We examined the role of the bicarbonate transport metabolon in the regulation of SLC26A6 Cl À /HCO 3 À exchange activity. We found that SLC26A6 is the first member of the SLC26A family confirmed to bind CAII, and is thus the first shown to form a transport metabolon. The binding site for CAII on SLC26A6 is adjacent to the PKC phosphorylation site responsible for inhibition of SLC26A6 transport. PKC disruption of CAII binding is coincident with a decrease in transport rate of SLC26A6. Taken together, our data support a new model for regulation of membrane transport: metabolon disruption. (Sterling et al, 2002b) , does not ( Figure 1A ). Seven potential CAB sites, consisting of a hydrophobic residue followed by four amino acids, with at least two acidic residues, were identified at the extreme C-terminus of the SLC26A6 protein (Vince and Reithmeier, 1998 ) ( Figure 1A ). To examine whether SLC26A6 cytoplasmic domain could bind CAII, a glutathione S-transferase (GST) fusion protein corresponding to SLC26A6 amino acids Q497-D633 (GSTA6-Q497-D633) was constructed. GST alone and GSTA6-Q497-D633 were resolved by SDS-PAGE and blotted onto a membrane. The blot was overlaid with CAII-containing lysates and the presence of CAII adherent to the blot assessed by immunoblotting. The blot showed specific binding of CAII to GSTA6-Q497-D633 ( Figure 1B ). Quantification of GST present in the GST and GSTA6-Q497-D633 bands ( Figure 1C ) and the amount of CAII bound to these bands revealed that the CAII/GST and CAII/GSTA6-Q497-D633 ratios were 0.0570.01 units and 1.4170.60 units, respectively (n ¼ 3, Po0.05). GSTA6-Q497-D633 thus binds 28 times more CAII than does GST alone. Binding of CAII to the Q497-D633 amino-acid region of the SLC26A6 C-terminus was further assessed by a solid-phase binding assay. CAII was immobilized on microtiter plates and incubated with different concentrations of GST and GSTA6-Q497-D633. GST associated with the plate was detected with an anti-GST antibody. GSTA6-Q497-D633 exhibited saturable binding to immobilized CAII, with a half-maximal binding occurring at 14177 nM (calculated from data corrected for GST binding alone, not shown), whereas GST alone bound nonspecifically, as indicated by the linearity of binding and lack of saturation ( Figure 2A ). We conclude that the Q497-D633 region may mediate the interaction of SLC26A6 with CAII.
Results

Physical and functional interactions between
To identify the CAB site in the C-terminal tail, we focused on five potential CAB sites in the Q497-D633 region. A series of GST fusion proteins were constructed, spanning the Q497-D633 region, but sequentially deleting the consensus CAB sites ( Figure 2B ). Microtiter dish-binding assays revealed that GSTA6-Q497-D633 and GSTA6-A531-D633 bound CAII, but no binding was detected for GSTA6-L570-D633 or GSTA6-N602-D633 ( Figure 2C ). We conclude that the SLC26A6 D546-F549 region binds CAII.
Since CAII binds the C-terminus of SLC26A6 with high affinity, we examined the influence of CAII on SLC26A6 HCO 3 À transport activity. Rates of pH i alkalinization (Cl À efflux phase of assays) were assessed for SLC26A6-transfected cells before and 10 min after treatment with the membrane-permeant CA inhibitor, ACTZ, 150 mM ( Figure 3A ).
ACTZ, which has no direct effects on the BTs so far examined (Cousin and Motais, 1976) , reduced the rate of pH i change associated with HCO 3 À movement by 5573% (n ¼ 3, Po0.05) ( Figure 3B ). As a control, two consecutive Cl À /HCO 3 À exchange assays were performed in the absence of ACTZ. In this case, the rates of pH i change in the consecutive assays were indistinguishable (not shown). The anion exchange inhibitor, 4,4 0 -diisothiocyanatostilbene-2,2 0 -disulfonic acid, disodium salt (DIDS) (1 mM), reduced the rate of transport by 9271% (n ¼ 3, Po0.05), as reported previously (Xie et al, 2002; Lohi et al, 2003) ( Figure 3B ). It is important to note that HEK293 cells endogenously express CAII (Sterling et al, 2001) . Results measured during HCO 3 À efflux (Cl À influx phase of assays) were essentially the same as those found during cellular alkalinization ( Figure 3B , black versus white bars). These data suggest that functional CAII is required for full SLC26A6 transport activity. All transport rates have been corrected for background activity of HEK293 cells transfected with empty vector. HEK293 cells express sufficient endogenous CAII to maximize HCO 3 À transport of overexpressed transporters (Sterling et al, 2001) . We thus used a dominant-negative approach to study the effect of CAII on Cl À /HCO 3 À exchange activity by (GenBank AF279265) , and SLC26A3 (GenBank L02785). Shading indicates sequence identity (black) and sequence similarity (gray). Potential CAII-binding sites, consisting of a hydrophobic residue followed by four residues, two of which are acidic, are indicated (black overline). Asterisks mark consensus PKC phosphorylation sites (Expert Protein Analysis System, http://ca.expasy.org/). (B-C) In all, 10 mg of either GST alone (1) or GSTA6-Q497D633 (2) were resolved by SDS-PAGE on 10% acrylamide gels and transferred to PVDF membranes. Blots were incubated with a lysate of HEK293 cells, which endogenously express CAII. Blots were then probed with anti-CAII antibody (B) or anti-GST antibody (C). Arrowheads indicate the migration positions of GST alone (open) and GSTA6-Q496-D633 (filled).
presence of endogenous wild-type (WT) CAII, displaces functional WT CAII from cytoplasmic binding sites (Sterling et al, 2001) . Figure 3B shows that overexpression of V143Y CAII decreased the rate of SLC26A6 bicarbonate transport rate by 3076% (n ¼ 5, Po0.05). These data suggest that the presence of cytosolic CAII is not sufficient to activate SLC26A6 transport; CAII needs to localize to the SLC26A6 CAB site.
The CAB site, identified as 546DVDF549 ( Figure 2C ), was mutated to 546NVNF549 in full-length SLC26A6 to generate SLC26A6-DCAB. The transport activity of the mutant was dramatically reduced in comparison to WT SLC26A6, by 5075% (n ¼ 3, Po0.05) ( Figure 3B ). Mutations sometimes reduce the efficiency of cell-surface processing of proteins. However, the reduced transport rate could not be explained by a reduction in cell surface expression since SLC26A6-DCAB expression at the cell surface was indistinguishable from WT SLC26A6 (Supplementary Figure 1; 2775 and 2875% of protein at the surface for WT and SLC26A6-DCAB, respectively). Taken together, our data demonstrate that CAII binds human SLC26A6 at 546DVDF549, which activates bicarbonate transport. This is the first demonstration that an SLC26A family member forms a bicarbonate transport metabolon.
Regulation of human SLC26A6 Cl
À /HCO 3 À exchange activity by AngII PKC-coupled signaling cascades inhibit luminal bicarbonate secretion in pancreatic duct, a process likely mediated by SLC26A6 (Hegyi et al, 2005) . AT 1a AngII receptors activate PKC (Thomas et al, 1996) . The effect of AngII-dependent signaling on SLC26A6 Cl À /HCO 3 À exchange was investigated in HEK293 cells transiently cotransfected with SLC26A6 and AT 1a AngII receptor cDNAs ( Figure 4A ). SLC26A6 caused changes of intracellular pH, associated with the coupled exchange of Cl À for HCO 3 À across the plasma membrane ( Figure 4A Figure 4B ). These results suggest that the decrease in SLC26A6 Cl À /HCO 3 À exchange activity upon treatment with AngII is mediated by PKC. Figure 4C shows similar expression levels for AT 1a receptors in HEK293 cells transfected with AT 1a alone or cotransfected with both AT 1a and SLC26A6 cDNAs. Similarly, strong immunoreactivity was present in lysates of HEK293 cells transfected with SLC26A6 cDNA, and probed with anti-SLC26A6 C-terminus antibody ( Figure 4D ). SLC26A6 migration as a broad band was previously found for SLC26A6 protein expressed in MDCK cells, suggesting that the protein might be heterogeneously glycosylated (Waldegger et al, 2001) . PKC phosphorylation sites, SQK (553-555), SPK (582-584), TLK (636-638), SLK (667-669), and TKK (706-708) (ExPASy Molecular Biology Server, http://www.expasy.org/tools/ scanprosite). Interestingly, S553 and S582 are close to the SLC26A6 CAB site (546DVDF549), which led us to consider that phosphorylation by PKC might decrease CAII/SLC26A6 interaction. To investigate this possibility, HEK293 cells were transfected with WT SLC26A6, or PKC consensus site mutants SLC26A6-S553A and SLC26A6-S582A. Transport activity of SLC26A6-S553A and SLC26A6-S582A did not differ significantly from WT SLC26A6, indicating that PKC consensus site mutants were fully functional ( Figure 5A ). Upon PKC activation with PMA, WT and S582A SLC26A6 were inhibited to a similar extent ( Figure 5A ). However, SLC26A6 DCAB and S553A had no significant response to PMA. These data suggest that both S553 and the CAB site have indispensable roles in regulation of SLC26A6 by PKC. The association of endogenously expressed CAII with SLC26A6 was further assessed in immunoprecipitates ( Figure 5B and C) . The amount of CAII bound to SLC26A6 was quantified on immunoblots and normalized to the amount of SLC26A6 expressed in each case. WT SLC26A6 and the PKC site mutants S553A and S582A bound CAII to the same extent, indicating that S553 and S582 are not required for CAII binding. However, SLC26A6-DCAB bound only about one-third as much CAII, confirming that the 546DVDF549 sequence mutated in SLC26A6-DCAB forms the major or only CAB site in SLC26A6. Using the same methodology, the influence of PKC on SLC26A6/CAII interaction was measured ( Figure 5D ). Treatment of WT SLC26A6-expressing cells with PMA resulted in a decrease of CAII binding to the same low level as SLC26A6-DCAB. This suggests that PKC phosphorylation disrupts the binding of CAII to SLC26A6. Consistent with this, treatment of SLC26A6-expressing cells with PMA, but not the inactive isomer a-PMA, led to phosphorylation of SLC26A6 (Supplementary Figure 2) .
Differences in transport activity of the SLC26A6 mutants could be explained by alterations of expression level or À exchange activity, relative to WT SLC26A6, for SLC26A6 or SLC26A6-DCAB expressed alone or coexpressed with functionally inactive V143Y CAII (n ¼ 4-6). *Po0.05. Rates were measured during HCO 3 À influx (black bars) and HCO 3 À efflux (white bars).
efficiency of protein processing to the cell surface. However, immunoblots showed similar expression levels for WT SLC26A6, SLC26A6-DCAB, SLC26A6-S553A, and SLC26A6-S582A mutants, when normalized by endogenous b-actin expression (Supplementary Figure 3) . Differences in the degree of cell surface processing of SLC26A6 variants do Mean values of anion transport activity relative to cells expressing SLC26A6 alone. Cells expressing AT 1a receptors were exposed to AngII (1 mM) either in the absence or presence of the PKC inhibitor, CHE (10 mM). SLC26A6-expressing cells were also exposed to 10 min treatment with PMA, either in the presence or the absence of the PKC inhibitor, CHE (10 mM). Rates were measured during HCO 3 À influx (black bars) and HCO 3 À efflux (white bars). *Po0.05, n ¼ 4-5. (C) HEK293 cells were either transfected with AT 1a R cDNA, or cotransfected with SLC26A6 and AT 1a R cDNAs. Samples were analyzed by SDS-PAGE, transferred to PVDF membranes, and probed with either anti-AT 1a R antibody (C) or anti-SLC26A6 antibody (D). not explain these findings, since there were no significant differences (Supplementary Figure 1A and B; 2775 , 2875 , and 2875% of protein at surface for WT, SLC26A6-DCAB, SLC26A6-S553A, and SLC26A6-S582A, respectively). Similarly, PMA did not affect the level of SLC26A6 expression at the plasma membrane (Supplementary Figure 1C) .
Taken together, we propose that phosphorylation of S553 in the SLC26A6 C-terminal tail displaces CAII from its binding site in the cytoplasmic domain of SLC26A6.
Colocalization of SLC26A6 and CAII in cells
Localization of SLC26A6 protein and endogenous CAII was assessed in cells treated with PMA or the biologically inactive isomer, 4-a-phorbol 12-myristate 13-acetate esters (a-PMA). As expected, SLC26A6 had a pericellular (plasma membrane) localization after PMA and a-PMA treatments ( Figure 6A) . In a-PMA-treated cells, CAII localized mainly to the plasma membrane ( Figure 6A, upper middle panel) . However, treatment with PMA displaced CAII from the plasma membrane ( Figure 6B and C, lower middle panel). Specificity of the CAII and SLC26A6 signals was shown by the absence of signal in samples treated with secondary antibody and no primary antibody (not shown). As a control, colocalization of CAII with the a 1a adrenergic receptor (a 1a R), expressed in transfected HEK293 cells, was also assessed by immunocytochemistry (not shown).
Quantitative analysis revealed that SLC26A6/CAII colocalization was significantly less in PMA-treated cells than in aPMA-treated cells, 5278% and 7075% overlap, respectively ( Figure 6B , Po0.05), indicating that PMA treatment reduced SLC26A6/CAII colocalization. a 1a R localizes to the plasma membrane, but colocalization with CAII was approximately one-third (2976%, Figure 6B ) that for SLC26A6, and treatment with PMA did not affect colocalization of a 1a R and CAII (3077%, Figure 6B ).
We further examined the CAII/SLC26A6, by confocal microscopy of the SLC26A6 mutants DCAB, S553A, and S582A (Supplementary Figure 4) . Quantitative analysis revealed that DCAB-SLC26A6 colocalizes with CAII to a very low extent, consistent with a failure to bind CAII ( Figure 6C ). S582A-SLC26A6 colocalized with CAII to a similar extent as WT-SLC26A6 and responded to PMA similarly to WT-SLC26A6 (Supplementary Figures 4B and 6C) . In contrast, S553A-SLC26A6 bound CAII like WT, but failed to respond to PKC activation ( Figure 6C ). Taken together, activation of PKC using PMA caused a displacement of CAII from SLC26A6 at the plasma membrane. Phosphorylation of S553 of SLC26A6 by PKC displaces CAII from the surface of SLC26A6.
Discussion
The data presented here support a new mechanism for regulation of membrane transport. BTs bind the cytosolic enzyme, CAII, at their cytosolic surface (Sterling et al, 2001; Dahl et al, 2003; Loiselle et al, 2004; Pushkin et al, 2004) . Localization of CAII, which produces the transport substrate HCO 3 À , activates the bicarbonate transport rate by maximizing the local concentration of HCO 3 À at the transport site. The complex of a BT with CA has been termed a bicarbonate transport metabolon (Sterling et al, 2001 ). Here we have shown for the first time that residues 546-549 of SLC26A6 form an essential part of a cytoplasmic CAII-binding site. The observation that mutation of the CAII-binding site significantly reduced SLC26A6 transport activity is consistent with a bicarbonate transport metabolon, where the CAII/transporter association maximizes the HCO 3 À transport flux. In SLC26A6-expressing cells, PKC activation resulted in (1) phosphorylation of SLC26A6, (2) reduction of SLC26A6 transport activity and (3) displacement of CAII from the cytosolic surface of the plasma membrane. Finally, the SLC26A6/CAII interaction was disrupted by PKC-mediated phosphorylation of the SLC26A6 C-terminal region. From these observations, we propose that PKC inhibits SLC26A6 HCO 3 À transport by disruption of the bicarbonate transport metabolon (displacement of CAII from the surface of SLC26A6) (Figure 7 ). This model was confirmed by the insensitivity of the CAB site mutant and the S553A mutant to PKC activation. We have thus determined the mechanism by which a phosphorylation event induces regulation of transport. Transport metabolon disruption, displacement of an enzyme that catalyzes production of a transport substrate from the binding site on the surface of the transporter, represents a new mechanism for regulation of membrane transporter function. While we present data only for the bicarbonate transport metabolon, metabolon disruption may represent a mechanism for acute regulation of transport activity by other transporters of cellular metabolites. The C-terminal cytoplasmic domains of SLC4A Cl À /HCO 3 À exchangers and Na þ /HCO 3 À cotransporters bind CAII, which activates their bicarbonate transport rate by maximizing the local concentration of HCO 3 À at the transport site (Alvarez et al, 2003; Loiselle et al, 2004; Pushkin et al, 2004) . This is the first demonstration that an SLC26A family transporter binds CAII to activate HCO 3 À transport, which demonstrates that CAII binding is found among all three groups of BTs that are known. Binding affinity of SLC26A6 for CAII (141 nM) was comparable to that seen previously for AE1 (20 nM) and NBC3 (101 nM) (Vince and Reithmeier, 1998; Loiselle et al, 2004) . In contrast, the C-terminal region of SLC26A3 does not contain a consensus CAB motif. Interestingly, binding of CAII by the kidney variant of the NBC1 Na þ /HCO 3 À cotransporter is enhanced following protein kinase A treatment of NBC1. However, a concomitant increase in transport flux was not observed (Gross et al, 2002) . Thus, there is precedent for modulation of CAII/bicarbonate interaction by phosphorylation, but this is the first example where modulation of the metabolon serves to regulate transport. Additional support for the idea of regulation of membrane transport by metabolon modulation comes from studies of the interactions between the NHE1 Na þ /H þ exchanger and CAII (Li et al, 2002) . NHE1 bound CAII at an unidentified site in the NHE1 cytoplasmic domain to activate Na þ /H þ exchange. Phosphorylation of NHE1 cytoplasmic domain by a heart cell lysate induced phosphorylation at multiple unidentified sites and a concomitant increase in NHE1 CAII binding and transport activity, which is suggestive of metabolon modulation.
CAII
CAII/BT interaction is established to occur electrostatically between the positive N-terminal region of CAII and an acidic motif on the BT. It is thus surprising that PKC-mediated addition of a phosphate group adjacent to the SLC26A6 CAB site results in displacement of CAII/SLC26A6 interaction. In the absence of a high-resolution structure for the complex of CAII with a BT, it is not possible to provide a firm explanation for how this occurs. However, we can speculate that interactions between CAII and a BT are more extensive than the two minimal motifs (basic CAII tail and acidic BT tail). In fact, these two regions are likely too small to represent the complete interacting surface. The identified PKC site (S553) is close to, but not co-incident with, the CAB site. The addition of phosphate by PKC may result in an electrostatic repulsion at a site adjacent to the CAB site.
Our data may have significance for the regulation of pancreatic bicarbonate secretion, particularly in CF, where bicarbonate secretion is compromised. SLC26A6 may contribute to pancreatic duct HCO 3 À secretion at levels up to 140 mM (Lohi et al, 2000; Ko et al, 2002; Steward et al, 2005) . Activation of PKC reduces anion secretion in pancreatic duct cells (Cheng et al, 1999) , which could be explained by effects on Cl À /HCO 3 À exchange activity of SLC26A6. The recent report that substance P acts through PKC to reduce DIDS-inhibitable pancreatic duct bicarbonate secretion (Hegyi et al, 2005) further supports a possible role of PKCmediated metabolon disruption in the regulation of pancreatic bicarbonate secretion. Our data suggest that reduction of pancreatic duct PKC activity and strategies aimed at increasing CAII interaction with SLC26A6 are targets for therapies to increase pancreatic bicarbonate secretion. STAS domains have emerged as the centre for regulation of SLC26A6 family transporters (Ko et al, 2004) . The STAS domain of the proteins SLC26A3 and SLC26A6 mediates reciprocal regulation with the CF gene product, CFTR (Ko et al, 2004) . We found that the CAB site (546D-F549) and the PKC site responsible for reduction of SLC26A6 transport rate (S553) are both within the STAS domain of SLC26A6, which spans E530-A741 on the basis of sequence alignments (Ko et al, 2004) (Figure 8A ). The NMR structure for the STAS Figure 8 Structural basis for regulation of SLC26A6 by PKC: the STAS domain. (A) Multiple sequence alignment of the amino-acid sequence of a surface loop (yellow) in the STAS domain of human (h) SLC26A1-SLC26A11 (hA1-hA11) and the sporulation-specific sigma factor of B. subtilis, SPOIIAA. Conserved residues (black boxes) and conservative replacements (gray boxes) are indicated. The sequence for loop residues in SPOIIAA is highlighted (green). The CAII-binding site (red) and consensus PKC phosphorylation site (blue) are present only in SLC26A6. (B) Structural model of the STAS domain from SPOIIAA (PDB code 1BUZ) (Kovacs et al, 1998) . Yellow structure highlighted with an arrow indicates the position of the variable loop between helix 1 and strand 3 (corresponding to the sequence highlighted in yellow in panel A). Cylinders represent a-helices and arrows represent b-sheets. N, amino-terminus; C, carboxyl-terminus. (C) Space-filling model of SPOIIAA oriented as in panel B. Loop region residues are yellow, while positive and negative residues are blue and red, respectively. Structures were rendered with Cn3D software.
